How Much Does Wegovy Cost in Montana in 2026?

Wegovy Retail Pricing in Montana

Brand-name Wegovy carries a manufacturer list price of $1,349 per month, and Montana retail pharmacies generally charge that full amount to uninsured patients. This figure reflects the wholesale acquisition cost (WAC) set by Novo Nordisk and has remained stable through early 2026 [1].

Prices can vary slightly between independent pharmacies and national chains like Walgreens, CVS, and Albertsons locations across the state. However, price differences between Montana pharmacies rarely exceed $30 to $50 in either direction. Rural pharmacies in communities like Miles City, Havre, or Lewistown may carry limited stock, which can add shipping delays but typically does not change the per-unit cost. Patients filling at retail should call ahead to confirm availability, because supply constraints that affected semaglutide products in 2023 and 2024 have mostly resolved but occasional spot shortages still occur at lower-volume pharmacies.

The $1,349 monthly figure covers the maintenance dose of 2.4 mg once weekly. During the 16-week titration phase, the per-pen cost is the same even though the delivered dose is lower (0.25 mg, 0.5 mg, 1.0 mg, or 1.7 mg), because each titration pen is packaged as a single-dose auto-injector supplied in monthly cartons [1].

Montana Medicaid and Wegovy Coverage

Montana Medicaid does not cover Wegovy for chronic weight management as of May 2026. This aligns with a broader pattern among state Medicaid programs. Anti-obesity medications have historically been excluded from Medicaid formularies under a provision in the Social Security Act (Section 1927(d)(2)) that allows states to exclude drugs used for "anorexia, weight loss, or weight gain" from mandatory coverage [2].

The federal Treat and Reduce Obesity Act has been reintroduced in Congress multiple times without passing. If enacted, it would remove the optional exclusion and require state Medicaid programs to cover FDA-approved anti-obesity medications. Montana has not independently moved to add Wegovy to its preferred drug list.

Patients enrolled in Montana Medicaid who have a BMI ≥40 or a BMI ≥35 with obesity-related comorbidities may still qualify for bariatric surgery coverage, which the state does cover under certain prior authorization criteria. For patients who prefer pharmacotherapy, the options within Medicaid remain limited to older, less effective agents. Dr. Caroline Apovian, who co-authored the 2015 Endocrine Society clinical practice guidelines on obesity pharmacotherapy, noted that "the exclusion of anti-obesity medications from Medicaid formularies disproportionately affects lower-income populations who carry the highest obesity burden" [3].

Commercial Insurance Coverage in Montana

Several commercial insurers operating in Montana now include Wegovy on their formularies, though coverage varies by plan tier and employer benefit design. Blue Cross Blue Shield of Montana, PacificSource, and some self-funded employer plans have added Wegovy with prior authorization requirements.

Typical prior authorization criteria include:

• Documented BMI ≥30, or BMI ≥27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea)
• Evidence of a structured diet and exercise program for 3 to 6 months
• No concurrent use of other GLP-1 receptor agonists
• Prescriber attestation that the medication is for chronic weight management

Even with coverage, out-of-pocket costs depend on the plan's specialty pharmacy tier. Patients on high-deductible health plans may face the full $1,349 until meeting their deductible. Preferred formulary placement can reduce the copay to $150 to $300 per month, and some plans with the most favorable tier placement bring it under $100.

Montana state employees covered under the state group benefit plan should check with the Department of Administration's benefits division, as formulary decisions for state plans are updated annually and may differ from commercial market offerings.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings program that can reduce out-of-pocket costs to $0 for eligible patients. The card applies to commercially insured patients whose plans cover Wegovy but impose a copay or coinsurance.

Key terms of the savings card as of 2026:

• Maximum benefit of $500 per 28-day fill
• Available for up to 13 fills (roughly one year of treatment)
• Not valid for patients on Medicare, Medicaid, TRICARE, or other government-funded programs
• Requires an active commercial insurance plan that covers Wegovy

For a Montana patient with a $200 monthly copay, the savings card would cover that entire amount. For a patient whose plan assigns Wegovy to a specialty tier with 30% coinsurance (roughly $405 on a $1,349 fill), the card would cover $405 per fill, staying within the $500 cap. Patients should enroll through the Wegovy savings card portal or ask their prescribing clinician's office to apply the card at the point of prescribing.

Patients without any insurance coverage do not qualify for the savings card. Cash-pay patients may instead check Novo Nordisk's patient assistance program (PAP), which provides Wegovy at no cost to patients who meet income thresholds (generally below 400% of the federal poverty level).

Compounded Semaglutide 2.4 mg in Montana

Compounded semaglutide 2.4 mg is available in Montana through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and may compound semaglutide when a valid patient-specific prescription exists. The typical cost is approximately $199 per month, a significant reduction from the $1,349 brand-name price [4].

A few things Montana patients should understand about compounded semaglutide:

FDA position. The FDA placed semaglutide on its drug shortage list from 2023 through early 2025, during which time 503A and 503B compounding was permitted under federal shortage provisions. As of 2026, the shortage status has been resolved for certain presentations. The FDA has taken enforcement actions against some compounders, and the legal status of compounded semaglutide remains subject to ongoing regulatory review [4].

Quality considerations. Compounded medications are not FDA-approved products. They do not undergo the same manufacturing, testing, and labeling review as branded Wegovy. The Endocrine Society and the Obesity Medicine Association have both cautioned that compounded GLP-1 receptor agonists may vary in potency, sterility, and stability. Patients choosing compounded semaglutide should verify that their pharmacy holds a current Montana Board of Pharmacy compounding license and follows USP 797 sterile compounding standards.

Salt form differences. Some compounding pharmacies dispense semaglutide sodium rather than the semaglutide base used in Wegovy. The clinical equivalence of semaglutide sodium at the same milligram dose has not been established in controlled trials, and dosing may not be directly interchangeable.

Dr. Harold Bays, Chief Science Officer of the Obesity Medicine Association, has stated that "patients deserve access to affordable anti-obesity medications, but they also deserve assurance that what they inject meets consistent pharmaceutical standards" [5].

Wegovy via Telehealth in Montana

Montana permits telehealth prescribing of Wegovy, and several national telehealth platforms serve Montana residents. The Montana Board of Medical Examiners requires that prescribing clinicians hold an active Montana medical license or practice under an interstate compact that covers the state.

Telehealth can be especially practical for patients in rural Montana counties where obesity medicine specialists are scarce. Montana ranks among the least densely populated states in the country, and many residents live more than 60 miles from the nearest endocrinologist or obesity medicine physician. A telehealth consultation typically costs $99 to $199 for an initial visit, with follow-up visits ranging from $49 to $99.

Patients using telehealth for Wegovy should confirm that their provider will:

• Order baseline labs (lipid panel, HbA1c, hepatic function, thyroid function)
• Conduct a medical history review that screens for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, both contraindications to GLP-1 receptor agonist use [1]
• Provide ongoing monitoring during dose titration
• Coordinate with a local pharmacy or ship medication directly

Some telehealth platforms bundle the consultation fee with compounded semaglutide, offering all-in pricing between $249 and $399 per month. Patients should ask whether the quoted price includes the medication itself and whether brand-name Wegovy (rather than a compounded product) is available through that platform.

Clinical Efficacy: What STEP-1 Showed

The approval of Wegovy rested primarily on the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program. In STEP-1 (N=1,961), adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity received semaglutide 2.4 mg or placebo once weekly for 68 weeks, alongside lifestyle intervention [6].

Results were definitive. The semaglutide group lost 14.9% of baseline body weight versus 2.4% in the placebo group (estimated treatment difference: -12.4 percentage points; P<0.001). A total of 86.4% of semaglutide-treated participants achieved ≥5% weight loss, compared with 31.5% on placebo. One-third of the semaglutide group lost ≥20% of body weight [6].

Gastrointestinal side effects were the most common adverse events. Nausea occurred in 44.2% of semaglutide-treated participants versus 17.4% on placebo, though it was mostly mild to moderate and tended to diminish after the first 8 to 12 weeks of treatment. The discontinuation rate due to adverse events was 7.0% in the semaglutide group versus 3.1% on placebo [6].

The SELECT cardiovascular outcomes trial (N=17,604) later demonstrated a 20% reduction in major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) with semaglutide 2.4 mg versus placebo in adults with overweight or obesity and established cardiovascular disease, over a median follow-up of 39.8 months [7]. This finding led to an expanded FDA indication for cardiovascular risk reduction and has influenced some insurer coverage decisions.

Practical Savings Strategies for Montana Patients

Montana patients looking to reduce their Wegovy costs have several options worth exploring in a specific order.

Step 1: Check your insurance formulary. Call the number on the back of your insurance card and ask whether Wegovy (NDC 00169-4100-XX) is covered, on which tier, and what prior authorization criteria apply. If covered, ask about your expected copay at a preferred specialty pharmacy.

Step 2: Apply the Novo Nordisk savings card. If commercially insured with coverage, this can reduce your copay to $0. The card stacks on top of your insurance benefit.

Step 3: If uninsured or underinsured, check the Novo Nordisk PAP. Income-eligible patients can receive brand-name Wegovy at no cost.

Step 4: Consider compounded semaglutide from a licensed Montana 503A pharmacy. At roughly $199 per month, this is the lowest-cost option, but it carries the quality and regulatory caveats described above.

Step 5: Ask about clinical trials. ClinicalTrials.gov lists active obesity pharmacotherapy studies, and some Montana-based or telehealth-accessible trials provide study medication at no cost.

Patients should be wary of online pharmacies or wellness clinics offering "semaglutide" at prices that seem unusually low (under $100 per month). Products at that price point may be research-grade peptides not intended for human injection, or they may originate from unlicensed compounders operating outside state pharmacy board oversight.

How Montana Compares to Neighboring States

Montana's pricing and coverage profile sits in a common position among Northern Plains and Mountain West states. Wyoming, Idaho, and the Dakotas also have Medicaid programs that exclude anti-obesity medications. Cash-pay pricing is similar across these states because wholesale acquisition costs are nationally uniform.

The variable that differs most between states is commercial insurance penetration. Montana's individual market is relatively small, with PacificSource and Blue Cross Blue Shield of Montana as the dominant carriers on the state exchange. Employer-sponsored plans vary widely. Large national employers with self-funded plans (common in Montana's mining, energy, and federal sectors) may offer more generous formulary coverage than small-group plans purchased through the state's SHOP marketplace.